1. Treatment of non-systemic juvenile idiopathic arthritis.
- Author
-
Shenoi S, Horneff G, Aggarwal A, and Ravelli A
- Subjects
- Child, Humans, Methotrexate therapeutic use, Sulfasalazine therapeutic use, Treatment Outcome, Arthritis, Juvenile drug therapy, Antirheumatic Agents therapeutic use, Arthritis, Psoriatic drug therapy
- Abstract
In the past two decades, the treatment of juvenile idiopathic arthritis (JIA) has evolved markedly, owing to the availability of a growing number of novel, potent and relatively safe therapeutic agents and the shift of management strategies towards early achievement of disease remission. However, JIA encompasses a heterogeneous group of diseases that require distinct treatment approaches. Furthermore, some old drugs, such as methotrexate, sulfasalazine and intraarticular glucocorticoids, still maintain an important therapeutic role. In the past 5 years, information on the efficacy and safety of drug therapies for JIA has been further enriched through the accomplishment of several randomized controlled trials of newer biologic and synthetic targeted DMARDs. In addition, a more rational therapeutic approach has been fostered by the promulgation of therapeutic recommendations and guidelines. A multinational collaborative effort has led to the development of the recommendations for the treat-to-target strategy in JIA. There is currently increasing interest in establishing the optimal time and modality for discontinuation of treatment in children with JIA who achieve sustained clinical remission. The aim of this Review is to summarize the current evidence and discuss the therapeutic approaches to the management of non-systemic phenotypes of JIA, including oligoarthritis, polyarthritis, enthesitis-related arthritis and psoriatic arthritis., (© 2024. Springer Nature Limited.)
- Published
- 2024
- Full Text
- View/download PDF